Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity

In Vivo

Volumn 23, Issue 5, 2009, Pages 821-826

  Shaib, Walid ^a   Lee, Veronica ^b   Wasif Saif, M ^b,c  

^a HOSPITAL OF SAINT RAPHAEL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

5 Fluorouracil; Bolus; Capecitabine; Cardiotoxicity; Rectal cancer

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; FLUOROURACIL; MORPHINE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ANGINA PECTORIS; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; HOLTER MONITORING; HUMAN; MALE; RECTUM CARCINOMA; THORAX PAIN;

EID: 70350072614     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58(2): 71-96, 2008.
2. Pinedo HM and Peters: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6(10): 1653-1664, 1988.
3. Wolmark N, Colangelo L and Wieand S: National Surgical Adjuvant Breast and Bowel Project Trials in Colon Cancer. Sem Oncol 28(1 Suppl 1): 9-13, 2001. (Pubitemid 32173098)
4. Marsoni S: International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol 28(1 Suppl 1): 14-19, 2001.
5. Oconnell MJ: A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (5-FU) for the treatment of advanced colorectal cancer: experience of the Mayo Clinic and North Central Cancer Treatment Group. Adv Exp Med Biol 244: 173-184, 1988.
6. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450, 1990. (Pubitemid 20331943)
7. Oconnell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE and Figueredo A: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16(1): 295-300, 1998. (Pubitemid 28041612)
8. Porschen R, Bermann A, Löffler T, Haack G, Rettig K, Anger Y and Strohmeyer G: Arbeitsgemeinschaft Gastrointestinale Onkologie. 5-Fluorouracil plus leucovorin is effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. J Clin Oncol 19(6): 1787-1794, 2001.
9. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV and Mayer RJ: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stageII and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23(34): 8671-8678, 2005.
10. Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE and Macdonald JS: Phase III southwest oncology group 9415/intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23(9): 1819-1825, 2005.
11. Carrato A, Köhne C, Bedenne L for AIO/CAO, FFCD, TTD, EORTC: Folinic acid-modulated bolus 5-FU or infusional 5-FU or infusional 5-FU adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC-2 study. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 24: 18s. (abstr 3563), 2006.
12. Hickish T, Boni C, Tabernero J et al: FOLFOX4 as adjuvant treatment for stage II colon cancer: subpopulation data from the MOSAIC trial. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 22: 14s. (abstr 3619), 2004.
13. Kuebler JP, Wieand HS, Oconnell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS and Wolmark N: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25: 2198-2204, 2007.
14. Saif MW, Hashmi S, Zelterman D, Almhanna K and Kim R: Capecitabine vs. continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis 23(2): 139-145, 2008. (Pubitemid 350302509)
15. Anand AJ: Fluorouracil cardiotoxicity. Ann Phanrmacother 28(3): 374-378, 1994.
16. Akhtar SS and Alim KP and Bano ZA: Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 50(6): 441-444, 1993.
17. Saif MW, Szabo E, Grem J and Hamilton M: The clinical syndrome of 5-fluorouracil cardiotoxicity ASCO meeting, Proc Am Soc Clin Oncol 20: (abstr 1613) 2001.
18. Jensen SA and Sørensen JB: Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine Cancer Chemother Pharmacol 58(4): 487-493, 2006.
19. Minzuno Y, Hokamura Y, Kimura T, Kimura Y, Kaikita K and Yasue H: A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction. Jpn Circ J 59: 303-307, 1995.
20. Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U and Schmiegel W: 5-Fluorouracil induces arterial vasocontractions Ann Oncol 15(4): 661-664, 2004.
21. Shoemaker LK, Arora U and Rocha Lima CM: 5-Fluorouracil-induced coronary vasospasm Cancer Control 11(1): 46-49, 2004.
22. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB and Albertsson M: The influence of 5-fluorouracil on the endothelium of small arteries. An electron microscopic study in rabbits. Scan Microsc 9: 561-576, 1995.
23. Cwikiel M, Eskilsson J, Albertsson M and Stavenow: The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 7: 731-737, 1996.
24. Porta C, Moroni M, Ferrari S and Nasatasi G: Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 45: 81-82, 1998.
25. Clavel M, Simeone P and Grivet B: Cardiac toxicity of 5-fluorouracil.Review of the literature, 5 new cases. Presse Med 17(33): 1675-1678, 1988.
26. Wijesinghe N, Thompson PI and McAlister H: Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ 15(5): 337-339, 2006. (Pubitemid 44426248)
27. Rizvi AA, Schauer P, Owlia D and Kallal JE: Capecitabine-induced coronary vasospasm - a case report. Angiology 55(1): 93-97, 2004. (Pubitemid 38082545)
28. Mosseri M, Fingert HJ, Varticovski L, Chokshi S and Isner JM: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstrication of vascular smooth muscle. Cancer Res 53: 3028-3033, 1993.
29. Schöber C, Papageorgiou E, Harstrick A, Bokemeyer C, Mügge A, Stahl M, Wilke H, Poliwoda H, Hiddemann W and Köhne-Wömpner CH: Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72: 2242-2247, 1993. (Pubitemid 23280155)
30. Labianca R, Beretta G, Clerici M, Fraschini P and Luporini G: Cardiotoxicity of 5-fluorouracil: a study on 1,083 patients. Tumor 68: 505-510, 1982.
31. Robben NC, Pippas AW and Moore JO: The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 71: 493-509, 1993.
32. Eskilsson J and Albertsson M: Failure of preventing 5 flurouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 29: 1001-1003, 1990.
33. Cerny J, Hassan A, Smith C and Piperdi B: Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer 8(1): 55-58, 2009.
34. Alter P, Herzum M, Soufi M, Schaefer JR and Maisch B: Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 4(1): 1-5, 2006.
35. Rezkalla S, Kloner RA, Ensley J, al-Sarraf M, Revels S, Olivenstein A, Bhasin S, Kerpel-Fronious S and Turi ZG: Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 7: 509-514, 1989.
36. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A and Tsavaris N: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134(1): 75-82, 2008. (Pubitemid 350060687)
37. Könne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R and Dörken B: Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil- associated cardiotoxicity. Br J Cancer 77: 973-977, 1998.